Illumina Stock - Analyst consensus and momentum snapshot

Illumina stock remains a momentum name in US genomics, with a broadly neutral analyst consensus and a double-digit year-to-date gain. On Wednesday the focus is on operations and strategy while investors weigh the medium-term growth narrative.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 16:06 UTC. Details in the imprint.

Illumina (US4523271090) is one of the established names in genomic sequencing and analysis. With no fresh company or regulatory releases on Wednesday, the focus turns to analyst consensus data and the company’s operational momentum in core markets.

What analyst data show

Illumina stock currently carries a consensus rating of Hold among Wall Street analysts, according to data compiled by MarketBeat. The consensus price target is about $142 per share, implying downside versus the latest traded levels.

Recent data also highlight that Illumina has been cited as a top momentum stock candidate for long-term investors in separate research coverage, reflecting its share price recovery and sector positioning. That said, target prices and ratings remain mixed across individual houses.

Operations and growth narrative

Operationally, Illumina focuses on DNA sequencing systems, consumables and informatics tools used by research institutions, hospitals and biotech companies worldwide. Management has emphasized oncology, genetic disease and reproductive health as key application areas in recent strategy updates.

To support this strategy, the company develops new versions of its DRAGEN secondary analysis software, including pipelines aimed at oncology and single-cell research. These tools are designed to help customers process large genomic datasets more efficiently in clinical and research environments.

How the company makes money

Illumina generates revenue primarily from selling sequencing instruments such as its NovaSeq and NextSeq platforms, alongside recurring consumables and related services. Software products like the DRAGEN analysis suite add further high-margin revenue streams linked to installed instruments.

Where the stock trades today

Illumina shares (US4523271090) trade on the Nasdaq at around $165 in recent Wednesday trading, according to composite quote data, with the latest observable quotes in the mid-$160 range during US market hours.

Key facts on Illumina stock

• Company: Illumina Inc.
• ISIN: US4523271090
• WKN: 927079
• Ticker: ILMN
• Venue: Nasdaq
• Price (as of 06/17/2026, 16:00 UTC): roughly $165.00
• Market cap: roughly $26 billion (as of mid-June 2026)
• Sector / Industry: Health Care / Life Sciences Tools & Services
• Index membership: Standard & Poor's 500 index
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.